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ABSTRACT 
 
Glutamic Acid Decarboxylase (GAD) antibodies are markers of type 1 diabetes mellitus (T1DM) and 
autoimmune neurological syndromes. The main neurological syndromes linked to GAD abs are stiff-person 
syndrome (SPS), cerebellar ataxia, limbic encephalitis and epilepsy. Titers of GAD abs in neurological patients 
are much higher than in diabetes. The meaning of low titres in neurological syndromes is still uncertain and the 
cut off for the relevance of GAD abs is debated. Moreover, commercial kits for detection of GAD abs are usually 
validated only in patients with T1DM.  
Our work aims:  
- to perform a clinical validation of a commercial ELISA assay for GAD abs detection in serum and 
cerebrospinal fluid (CSF) of patients with suspected neurological autoimmune diseases;  
- to set up a clinically relevant cut-off for serum GAD abs;  
- to explore the meaning of serum low-titre GAD abs in neurological patients;   
- to investigate the presence of coexisting antineuronal antibodies in GAD abs seropositive patients; 
We tested 330 patients with suspected autoimmune neurological syndromes for GAD abs by a modified 
commercial ELISA kit. Sera and CSF were titrated by multiple dilutions and the final values extrapolated by a 
mathematical model. When paired serum and CSF were available, intrathecal synthesis was calculated. 
Specimens were also tested for other antineuronal abs (onconeural and surface antigens) by a cell-based assay  
and immunoblot; GAD abs were searched also by immunoistochemistry on frozen rat brain and immunoblot.  
Clinical features were reviewed by one observer blinded for GAD titers; he noted if a typical GAD-related 
autoimmune neurological syndrome was present; then a ROC curve was generated to find the best cut off that 
distinguishes clinically relevant from clinically not relevant titres. 
Forty-three patients tested positive by optimized ELISA (serum GAD abs, range 6 – 2019681 UI/ml), 35 with 
available clinical information were included (14 males and 21 females, age range 15-82 years old). In 26/35 
patients (74%) the final diagnosis belonged to the already reported spectrum of GAD-abs related diseases, 
specifically 10 patients diagnosed with encephalitis, 9 with SPS, 5 with ataxia and 2 with epilepsy. Among these, 
12/26 failed to fit the criteria described in the methods and were noted as “Atypical”. 14 patients showed typical 
features. ROC analysis identified a cut off at 13000 IU/ml. Intrathecal synthesis of GAD abs were detected in 9 
patients with serum high-titre GAD abs. One patient with a high GAD-abs titre showed co-reactivity with 
anti-Amphyphisin abs; 4/36 (11%) with low-titre GAD abs had a relevant neuronal surface antibodies positivity 
for anti-LGI1 (3) and anti-GlyR antibodies (1).   
We confirmed clinical spectrum of GAD autoimmunity. The study validates a modified ELISA in routine 
detection of GAD abs in neurological patients, setting the threshold of 13000 IU/ml as a discriminant serum cut 
off to identify clinically relevant GAD abs.    
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INTRODUCTION 
 
Glutamic Acid Decarboxylase 
Glutamic Acid Decarboxylase (GAD) is an essential enzyme producing Gamma-aminobutyric acid (GABA) 
from Glutamate. GABA is the most important inhibitory neurotransmitter of the central nervous system (CNS) 
and is involved in the control of neurogenesis and tissue development. [1]   
In mammals two isoforms of GAD exist, termed GAD67 and GAD 65 according to their molecular weights; they 
are coded by GAD1 and GAD2 genes and are located on chromosome 2 and 10, respectively. [2] Gene knockout 
studies underline the function of the isoforms: GAD1-/- mice have reduced GABA levels and die at the birth of 
the cleft palate [3]; GAD2-/- mice have normal basal GABA levels and develop fatal epilepsy and anxiety 
phenotype [4]. GAD67 is cytosolic and constantly active to produce basal levels of GABA. GAD65 is associated 
with the membrane of synaptic vesicles anchored to the cytoplasm-facing side and produces GABA when 
additional neurotransmitter is required (for example in stress responses). [5] 
Both isoforms consist of three functional domains: an amino (N)-terminal domain, containing the 
membrane-binding sequence and anchoring GAD65 to vesicles, a middle PLP-binding domain containing the 
catalytic site of the enzyme and a carboxy domain (C-terminal) [6]. GAD is located mainly in neurons, but also 
in pancreatic ß-cells.[7]  
 
GAD antibodies  
In 1988 antibodies to GAD (GAD abs) were first described in a patient affected with stiff person syndrome 
(SPS), epilepsy and type-1 diabetes mellitus (T1DM). [8]. Two years later, GAD abs were described in patients 
affected by autoimmune diabetes. [9] GAD abs have subsequently also been reported in Batten disease, [10] type 
1 autoimmune polyendocrine syndromes and further neurological syndromes like cerebellar ataxia, limbic 
encephalitis and palatal mioclonus [11].       
Although SPS and T1DM are both associated with GAD abs, the diseases do not always develop in the same 
subject. Indeed, only 1/10000 diabetic patient is or will be affected with SPS; viceversa, only 30% of SPS 
patients are diabetic [12]. This fact is not due to structural differences between pancreatic and neuronal isoforms 
(they are coded by the same genes, although a post-translational modification cannot be excluded). While low 
accessibility of the immune system to GAD in the central nervous system and the low expression of Major 
Histocompatibility Complex (MHC) by neurons may explain the low incidence of SPS in diabetic patients, it 
does not explain the high proportion of SPS without diabetes (about 70%). Several data support a different 
pattern of immune response (humoral and cellular) in the two diseases although a common genetic background 
has been found (e.g. DQ1B*0201 is a susceptibility allele among SPS and T1DM patients). [13] As regards the 
autoantibody repertoire, patients with SPS have GAD abs binding conformational epitopes of middle domain, 
C-terminal and linear epitopes in the first 100 aminoacids of the N-terminal domain. [14] [15] [16] 
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Conformational blockage of the C-terminal epitope seems to block the activity of the enzyme and this fact does 
not occur in diabetic patients. [17] Also N-terminal GAD antibodies are usually not found in diabetic patients but 
their pathogenic role is uncertain. [18]  
 
 
Figure 1. Molecular conformation of GAD (modified from [12]). Antibodies in SPS and T1DM are directed to different segments. 
 
It has been well established that GAD abs in neurological diseases are higher than in diabetes. According to 
some authors, the pathogenic diversity depends on this difference rather than a different pattern of antigenic 
recognition of GAD. [19].    
GAD65 abs are the principal biomarker due to greater autoantigenicity [20] but GAD67 antibodies are also 
found, especially in neurological patients. 50-60% of patients affected by a neurological syndrome whose serum 
harbours GAD abs also have anti-GAD67 abs, whereas only 12% T1MD have anti-GAD67 abs due to 
cross-reaction mechanisms. [21] [22] A recent paper by Gresa-Arribas et al. [16] showed that in a cohort of 
patients with GAD-correlated neurological diseases GAD67 abs were always found in the CSF, even in those 
cases whose serum was positive for GAD65 only.  
The predominant IgG isotype was found to be IgG1; in a minority of patients IgG2 and IgG3 were usually found 
at lower titres. [23] [24] 
Oligoclonal bands (OCB) are a frequent finding in CSF from patients affected by GAD abs diseases. Differences 
have been shown in the epitope specificity of GAD abs from serum and CSF from the same patient [25] 
suggesting intrathecal production by active B cells in the CNS.  
 
Pathogenicity of GAD antibodies  
The pathogenetic role of GAD abs in neurological diseases has not been established. The localization of the 
protein makes pathogenicity unlikely.  
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The heterogeneity of manifestations supports the hypothesis that other immune or cellular mechanisms are 
involved in the pathogenesis of the diseases. It has been reported that passive transfer from an SPS mother to 
newborns occurs without causing congenital forms of disease. [26]. There is no correlation between abs titres 
and the severity of the disease [27], although this fact is observed in other well established autoimmune diseases 
like myasthenia gravis. Up to now, no animal models of disease are available. [28] Moreover GAD abs 
neurological syndrome responds to immunotherapy less than diseases recently described in association with 
Neuronal Surface antibodies (NSabs), like anti-NMDAR or anti-LGI1[23].     
Several studies in vitro and in vivo, have addressed the issue of the pathogenic role of GAD abs (Table 1).  
 
Study Main findings 
Dinkel, 1998 [17] 
Inhibition of C-terminal segment of the GAD by a non-competitive 
mechanism in SPS patients (rat cerebellar extracts) and not in T1DM 
Ishida, 1999 [29] 
Ig from serum and CSF from a CA patient suppresses GABAergic 
suppression in rat cerebellar sclices 
Mitoma, 2000 [30] 
CSF Ig from an ataxic patient decreased GABA release onto Purkinje 
cells 
Takenoshita, 2001 [31] 
In rat cerebellar slices exposition to serum or CSF from patients with CA 
produced a gradual decreased of the inhibitory postsynaptic currents in 
Purkinje cells 
Vianello, 2008 [32] 
Increase in postsynaptic inhibitory potentials in hippocampal cultured 
neurons exposed to GAD abs 
Manto, 2007 [28] 
Intracerebellar and paraspinal injection of IgG from SPS patients induced 
continuous motor activity in rats 
Manto, 2011 [33] 
Abs from SPS patients increased glutamate levels and inhibit GAD 
activity in rats; Abs from patients with cerbellar ataxia had no effect on 
glutamate levels 
Hampe, 2013 [34] 
Intracerebellar injection of GAD abs against some specific epitopes 
determined impaired procedural spatial functions in rats 
Hansen, 2013 [35] 
Intraventricular injections of purified IgG GAD abs from a SPS induced 
stiffness-like behavior 
 
Table 1. Studies exploring pathogenicity of GAD abs 
 
The open issue of the wide clinical spectrum (but a single antibody positivity) has been addressed in some recent 
studies. [36] In 2015, some authors explored the hypothesis that distinct GAD antibodies could elicit specific 
phenotypes, finding that antibodies present in cerebellar ataxia and SPS recognized an epitope distinct from 
T1DM and limbic encephalitis. In the same year Gresa-Arribas et al [16] did not identify differences in the 
GAD epitope repertoire among the main examined neurological syndromes but found higher titres of GAD65 
6 
 
abs in the CSF of patients affected by limbic encephalitis or cerebellar ataxia compared to those with SPS. This 
latter work did not find further surface antibodies like anti-gephyrin and GABARAP, which had previously been 
suggested as possibly having co-reactivity with more pathogenetic value [19]; moreover, only 11% of cases 
harboured other NsABs (GABAaR and GlyR) but no SPS patient had coexisting GlyR, as found elsewhere in 
15% of patients. [37]        
The pathogenetic role of GAD abs is supported also by the demonstration that SPS patients have intrathecal 
synthesis of GAD abs (more in cerebellar ataxia than in SPS [11] [38]) and GAD-specific oligoclonal bands in 
CSF [39], even if this notion has been criticized [40]. 
 
Pathopysiology of GAD abs related diseases 
Experimental and clinical data strongly support the role of GABAergic dysfunction in neurological diseases 
associated with GAD abs. Improvement after administration of benzodiazepines or other GABA receptor 
agonists, like baclofen, is a feature of SPS patients that has been recognized since the earlier descriptions. Floeter 
et al [41] proved through the study of H-reflex that the clinical features of SPS were explained by the lack of 
spinal inhibitory GABAergic mechanisms.      
In vitro studies, especially on rat cerebellar slices, have suggested that cerebellar ataxia could be mediated by 
selective impairment of presynaptic GABAergic transmission from cerebellar basket and stellate cells to 
Purkinje cells which project into the deep cerebellar and vestibular nuclei. Impaired GABAergic projection 
within the brainstem could explain the oculomotor dysfunction common in these subjects. [42]  
Reduction of GABA levels were reported in GAD abs positive patients affected with temporal lobe epilepsy; [43] 
this could lead to impairment of GABAergic inhibitory tone determining epileptic manifestations. [44] 
 
Pathology 
Pathological studies in SPS show chromatolysis and vacualisation of the anterior horn cells and a loss of 
alpha-motor, gamma-motor neurons and spinal interneurons with gliosis. Perivascular lymphocytic cuffing in 
different CNS regions has been shown in PERM and SPS with brainstem signs. [12] In cerebellar ataxia, loss of 
Purkinje cells with preservation of basket cells in the molecular layer has been shown. Proliferation of the 
Bergmann glia has also been reported. [45] [46]. Loss of pyramidal cells and inflammatory infiltrates have been 
reported in patients affected by limbic encephalitis with high titres of GAD abs in serum. [47]      
 
Laboratory detection of GAD abs 
Several methods are routinely used in clinical practice to detect GAD abs: immunohistochemistry (IHC), 
radioimmunoassay (RIA) and enzyme-linked immunosorbent assay (ELISA). More rarely and for research 
purposes immunoprecipitation assay and radiobinding assay are also used. [48] Notably, to date there are no 
assays that unambiguously distinguish GAD abs specific for neurological diseases rather than diabetes. [11]  
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a) Immunohistochemistry 
IHC is considered the most specific technique for detecting GAD abs in neurological patients. Reactivity should 
be confirmed by RIA or another equivalent technique, according to general recommendations for the detection of 
antibodies in neurological patients. [49] IHC is positive only in samples with high-titre GAD abs (> 2000 IU/ml 
according to Saiz 2008 [11]     
Paraformaldeyhde-fixed frozen sections of rat cerebellum are incubated with serial dilutions of sera and/or CSF. 
The sections are incubated with peroxidase- or fluorescein-conjugated rabbit anti-human immunoglobulin and 
the reaction is usually developed with diaminobenzidine tetrahydrochloride and hydrogen peroxidase. [50] 
Positive sera stain the axon hillocks of Purkinje cells and diffuse nerve terminals in the molecular and granular 
layers of the cerebellum.   
 
b) Western Blot 
Total homogenate of human cerebellum is separated by sodium dodecylsulphate gel electrophoresis and 
transferred to nitrocellulose membrane. Strips are incubated with patients’ sera and polyclonal GAD abs 
(positive control) and then exposed to peroxidase-conjugated rabbit anti-human immunoglobulin. Immunoblot 
can also be performed using recombinant human GAD65 transferred to nitrocellulose; [48] some commercial 
kits use this system (dot-blot). 
 
c) Radioimmunoassay 
Serum samples are incubated with 125I-labelled human rGAD-65 and protein A-Sepharose is added. After 
centrifugation the precipitates are counted for 125I with a gamma scintillation counter. The results are 
interpolated in the standard curve constructed using dilution of a positive control serum. [51] 
 
d) Enzyme-linked immunosorbent assay 
In recent years ELISA has been replacing RIA for its practical advantages. These assays are performed using 
recombinant human GAD65 reacting with serum developed with a colorimetric method and using a plate reader 
to calculate optical density. Most commercial ELISA used to diagnose GAD abs neurological diseases are 
validated only for diabetic patients and designed to detect antibodies at low titres; moreover they sometimes do 
not use standardized units. Considering their important role in the clinical classification of diabetes, the 
Immunology of Diabetes Society (IDS) and the US Centers for Disease Control and Prevention, established a 
multicentre collaboration to improve and standardise the measurement of the autoantibodies predictive of type 1 
diabetes, included GAD abs. This was achieved by determining a standard unit of measure (International Units) 
and by periodic standardisation workshops. [52] 
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Clinical spectrum of GAD abs related neurological diseases: stiff person syndrome 
SPS is a rare disease (prevalence has been estimated at 1 in 1,250,000) initially described in men, but is more 
frequent in women (70%) [53]. Usually the disease starts in the mid-to-late 30s. [54] The first cases of “stiff man 
syndrome” were described in 1956, but the term was then replaced in 1991 by “stiff person syndrome” on the 
basis of the higher incidence in women. [55]  
The disease tends to have an insidious onset (but in some series, acute and subacute have been frequently 
reported [53]) with symmetric rigidity or hypertonia due to co-contraction of antagonist muscles causing slow 
motion (“robotic gait”) resembling parkinsonism. Muscle hypertrophy and abnormal postures are frequent, 
leading to lumbar hyperlordosis. Stiffness extends from the trunk to the proximal and then distal limbs, 
determining gait disturbances with falls. Painful muscular spasms and startle response are other frequent 
findings; these phenomena are fluctuating and triggered by emotional upset and by tactile, auditory and visual 
stimuli. Moreover, exteroceptive or cutaneomuscular reflexes are enhanced and spread into muscles normally 
not involved in the reflex. [56] Chest spasms can determine respiratory disturbances in some cases. Rigidity 
improves during the sleep. [27] Brainstem manifestations include oculomotor disturbances like dysconjugate 
gaze, horizontal and vertical supranuclear gaze palsy, hypometric and slow saccades, impaired smooth pursuit, 
nystagmus and abduction deficits. Brisk reflexes are a frequent sign. Dysautonomic crisis with tachycardia, 
blood pressure instability and hyperthermia are reported. [57]. Psychiatric comorbidity is frequent: depression, 
anxiety, alcohol abuse and specific phobias are reported. Weakness and sensory disturbances are not usually part 
of the classical spectrum of SPS but other neurological signs can be present. [12] The disease usually has a 
chronic course and after a slow progression the condition stabilizes for years or decades. [56]   
 
Clinical variants of SPS are also described, in particular focal SPS, jerky SPS, progressive encephalopathy with 
rigidity and myoclonus (PERM) and paraneoplastic SPS (see below).  
Focal SPS often localizes to one of the lower limbs (stiff limb syndrome). The disease can be limited to that 
segment for many years or can spread to other districts, resembling the classical form of SPS. [58] When the 
upper limbs are involved paraneoplastic SPS should be suspected.  
When SPS presents with prominent myoclonus and jerking movements, it is termed “jerking SPS”. Myoclonus is 
also one of the prominent features of PERM that manifests in patients older than classical SPS patients (50-60 
years). This form of disease has a slow onset (but subacute forms are increasingly described) of proximal and 
distal rigidity, oculomotor dysfunction, dysphagia and ataxia due to brainstem involvement, dysautonomia, axial 
and limb rigidity with profuse sweating. Cranial nerve, brainstem and long tract signs involvement differentiates 
PERM from SPS. [56] Recently detection of Glycine receptor antibodies [59] in these patients, with or without 
the co-presence of GAD antibodies, suggests that PERM could be a distinct disease.  
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Diagnosis of SPS is based on clinical and electrophysiological data. Electromyography shows continuous 
motor-unit activity with normal morphology including at rest and during contraction of antagonist muscles, 
which normally causes relaxation of the segment. [54] This activity is better found in axial muscles 
(thoracolumbar paraspinal and rectus abdominis muscle). No sign of denervation is usually found and nerve 
conduction velocity is normal [56]    
Brain MRI is usually normal and can be helpful in differential diagnosis. CSF often shows signs of 
inflammation; oligoclonal immunoglobulin bands (IgG) are found in about 70% of cases; [60] less frequently an 
increase of cell and protein content is also encountered. High-titre serum GAD abs are considered supportive 
features, and their positivity is classically reported in 60% cases.This incidence varies according to clinical 
inclusion criteria and methods of detection. Their presence can be also found in CSF with intrathecal synthesis 
documented in the majority of patients when appropriately searched for. [39] 
 
The therapeutical approach is based on drugs enhancing GABAergic transmission, like diazepam (Type-A 
GABA receptor agonist) or baclofen (Type-B), and immunotherapy. Benzodiazepines alleviate stiffness and 
painful spasms; this fact can be considered as confirmation of diagnosis. Higher doses of benzodiazepines can be 
required during the course of the disease causing drowsiness which limits their use. Botulinum toxin and 
intrathecal baclofen have been used with frequent adverse reactions but without long-term benefit. [61] 
The benefit from immunotherapy has been demonstrated. Intravenous immunoglobulin (IVIG) showed efficacy 
in a randomized trial [62] Plasma-exchange has efficacy, although results vary [63] [64] [65], and it can also be 
used as maintenance therapy [66]. More recently, anti-B cell therapies with rituximab have been proposed but a 
recent double-blind placebo-controlled trial failed to show differences versus placebo in stiffness score at 6 
months. [67]  
 
Cerebellar ataxia 
Cerebellar ataxia (CA) associated with GAD abs is a rare disease accounting for about 2% of patients affected by 
sporadic ataxia. [68] It is probably the second most frequent disease associated with GAD abs.[69] [23]It most 
frequently affects women from the fifth or sixth decades of life. Rare familial cases have been reported in 
association with other autoimmune conditions. [70] Autoimmune comorbidity is very frequently reported in 
GAD abs CA, patients being affected with T1DM, thyroiditis, pernicious anaemia, polyglandular autoimmune 
syndrome, myasthenia and vitiligo. [71] CA can be paraneoplastic in about 10% of patients, with small cell lung 
carcinoma, thymoma and breast cancer being more frequently described. [72]  
CA tends to have a slow or insidious onset, but a subacute onset is also frequently reported. [42] In about 25% of 
patients transient vertigo or other neurological dysfunctions affecting the brainstem, like diplopia or dysarthria 
can occur in a prodromic phase. [23] Clinical manifestations consist chiefly of moderate/severe gait ataxia, limb 
ataxia (usually asymmetric), dysarthria, kinetic tremour and oculomotor deficits, namely central nystagmus. 
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Overlapping signs SPS-like have been reported, manifesting as muscle rigidity and spasms affecting especially 
the lower limbs. Moreover, also epilepsy can be associated in 13% of patients. [16] Usually the disease has a 
progressive course and can be disabling. 
Magnetic Resonance Imaging (MRI) of the brain can show mild atrophy especially a few years after the 
beginning of the illness. Diagnosis is made after careful exclusion of other causes, particularly genetic causes, 
and on the basis of GAD abs of high titre in the serum and/or CSF.  
Immune therapy generally consists of steroids and immunoglobulin; plasma-exchange, Rituximab and 
Mycophenolate have also been reported. Therapy has efficacy in about 50% of patients; improvement after 
immunotherapy is more common in patients with subacute onset. [23] 
 
Epilepsy 
Epilepsy was reported in association to SPS in the earlier descriptions; the first patient harbouring GAD abs 
described by Solimena had coexistent epilepsy. [8] Temporal lobe epilepsy was then established in association 
with GAD abs. [73] Globally, the frequency of GAD abs in epileptic patients is about 1-5%, [74] [75] although 
methods of detection and inclusion criteria are variable. Dubey in a consecutive recent series of patients with 
epilepsy of unknown etiology found 8% of patients harbouring high titer GAD abs (> 20 nmol/L) [76]            
Adult onset of temporal lobe epilepsy seems the phenotype that is associated with the finding of high titers GAD 
abs. [74] Some studies have focused on the resistance to anti-epileptic drugs and long duration [75] [77]  
These patients are more frequently women with autoimmune comorbidity. They have no clinical and 
radiological features of limbic encephalitis, in particular they may have a chronic onset and usually a negative 
brain MRI. Epilepsy is also found as a feature of other GAD-abs-associated diseases, like stiff person syndrome 
or cerebellar ataxia.  
There are not sufficient data to assess the benefit of immunotherapy in GAD abs epilepsy; in the series by Quek 
et al 2012, [78] 3 out of 5 GAD65-seropositive patients (60%) reported benefit from immunotherapy with 
variable regimens. In the study by Toledano et al. 2014 there was a high representation of GAD positive patients 
in a non responder group to immunotherapy for patients with presumed autoimmune epilepsy. [79] Some authors 
suggest the benefit from chronic immune-suppression rather than “first line” therapy. [74]   
 
Limbic encephalitis 
GAD abs have recently been described in encephalitis with involvement of limbic areas. [47] Non-infectious 
limbic encephalitis (LE) is an inflammatory clinico-pathological entity that can be paraneoplastic or non 
paraneoplastic. [80] In the last ten years several neural antibody markers have been described; they are classified 
on the basis of their antigenic target in intracellular and membrane antibodies. [81] 
In recent years growing evidence has been accumulated that GAD abs can also associated with LE. Malter in 
2010 found GAD abs in 17% of a cohort of patients collected prospectively. Patients developed a chronic form 
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of inflammation of the temporal lobes with prominent epileptic features; they were younger and more frequently 
women as compared to patients with Voltage-Gated Potassium Channel-abs (VGKC) LE. They were resistant to 
immunotherapy with poor memory outcome. [47] In the series of GAD abs neurological patients reported by 
Saiz, LE were described in two cases (females aged 47 and 49) and in one case of paraneoplastic origin in a 
70-year-old male patient. [11] Five other patients affected by paraneoplastic LE were described by Arino (see 
below ). [82] 
From a clinical point of view, LE associated with GAD abs present with the classic triad of memory deficit, 
psychiatric symptoms and epileptic seizures, which have recently also been listed in the clinical criteria. [83] No 
specific clinical findings have been found in GAD-abs LE. Similarly to the other diseases, co-existence with 
other autoimmune diseases like T1DM and thyroiditis has been frequently reported.  
Brain imaging by MRI shows the typical hyperintensity of mesio-temporal lobes, without contrast enhancement.   
Compared with LE associated with neuronal surface antibodies, response to therapy is poorer; in a recent review 
of 58 published cases, only 4 were noted as fully responding to treatment.  
 
Paraneoplastic diseases 
SPS can be diagnosed in association with systemic neoplasms in less then 10% of cases. In these cases 
amphyphisin antibodies can be found, although in a minority of patients. Typically they are women affected by 
breast cancer, in whom low titres of GAD abs can coexist [84]  Differently from classic SPS, the neck and 
upper limbs are more frequently involved. Paraneoplastic SPS have also been described in association with 
isolated GAD abs and anti-Ri abs. [85] The associated tumours most frequently reported have been thymomas 
and breast cancer. Notably, PERM can also be paraneoplastic, e.g. it can be found in association with small cell 
lung cancer (Kyskan et al., 2013) and breast cancer [82]  
In the retrospective series reported by Arino in 2016, [82] when GAD abs occurred in association with limbic 
encephalitis or other classical paraneoplastic syndromes (cerebellar degeneration, opsoclonus-myoclonus 
syndrome or paraneplastic encephalomyelitis), with or without the co-existence of further antineuronal 
antibodies, the risk for cancer is higher than in patients with SPS or cerebellar ataxia (in particular lung cancer). 
Generally, paraneoplastic GAD autoimmunity is infrequent but in particular cases, oncological screening should 
be performed, especially in the presence of a classical paraneoplastic neurological syndrome. [82]   
 
Association with autoimmune diseases 
As different from autoimmune neurological diseases associated with other neural antibodies, GAD-abs-related 
diseases frequently coexist with other autoimmune diseases and this association was underlined in earlier reports 
[56]. T1MD, thyroiditis, pernicious anaemia, vitiligo are frequently associated, especially with SPS and 
cerebellar ataxia. Organ-specific antibodies are also a common finding, with or without the clinical manifestation 
of the disease.   
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3. AIM OF THE STUDY 
 
This project consists of a retrospective observational study describing a cohort of GAD abs seropositive patients 
affected with neurological diseases, whose samples were tested by an optimized commercial assay.  
The study aims to: 
- explore the clinical spectrum of GAD abs-related diseases, comparing data with literature; 
- to perform a clinical validation of a modified commercial ELISA kit to detect GAD abs, also at high levels, in 
serum and CSF of patients with suspected neurological autoimmune diseases; 
- to establish a threshold of clinical relevance for serum GAD abs determined by ELISA; 
- to clarify the meaning of serum GAD abs at low titers in neurological patients; 
- to assess if GAD abs coexist with other known antibodies. 
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METHODS  
Subjects  
We tested 330 patients with suspected autoimmune neurological disease, whose samples (serum and CSF) had 
been sent to our Laboratory between 2009 and 2015 for the detection of GAD abs. Patients with positive serum, 
available clinical information and at least 3 months follow-up were included in the study. 
Clinical information on positive patients was obtained retrospectively as part of clinical routine, from the 
referring physician through a structured questionnaire sent by e-mail.   
Analysis also included 215 consecutive samples from patients with suspected T1DM or polyglandular 
autoimmunity (whose neurological status was unknown), tested between September 2016 and September 2017. 
Moreover, 45 control sera from people affected with various neurological diseases and 8 from healthy people 
were included in the study. 
 
Review of clinical data 
One external physician, blind to GAD abs titration and to other antibody results, analyzed the collected clinical 
data. Firstly he reviewed the final diagnosis of the case and established whether it fitted with one of the four 
more frequently described clinical phenotypes of GAD abs, after careful exclusion of alternative causes: SPS 
(and variants), cerebellar ataxia, encephalitis and epilepsy. [11] He then had to judge whether the features of the 
case resembled typical features of GAD abs from the commonly recognized clinical spectrum, labeling the case 
as “typical” (Figure 2). 
 
 
 
Figure 2. Clinical revision process to assess typical patients 
 
Analysis of the external observer was arbitrarily based on the following core features, according to published 
data:  
a) stiff person syndrome [86]: 
- insidious onset of muscular rigidity of the limbs and axial (trunk) muscles with superimposed spasms 
- continuous co-contraction of agonist and antagonist muscles with inability to relax 
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b) cerebellar ataxia [42] 
- subacute or slow onset of gait ataxia and oculomotor abnormalities (nystagmus) 
- normal or cerebellar atrophy without brainstem atrophy 
- autoimmune comorbidity (see below)   
c) encephalitis [83] 
- subacute onset of working memory deficits, seizures, or psychiatric symptoms suggesting involvement of the 
limbic system 
- bilateral brain abnormalities on T2-weighted fluid-attenuated inversion recovery MRI, highly restricted to the 
medial temporal lobes 
- EEG with epileptiform discharges or slow wave-activity involving the temporal lobes (ictal or interictal) 
d) epilepsy  
- slow or acute onset of focal temporal epilepsy  
- drug resistant epilepsy  
- negative brain MRI  
- EEG with epileptiform discharges or slow-wave activity involving the temporal lobes (ictal or interictal) 
The following were supportive features used to consider the case as typical : 
- signs of inflammation in the CSF (pleocytosis, increased protein content or presence of oligoclonal bands) 
- presence of other autoimmune comorbidities (especially for cerebellar ataxia)    
- response to immunotherapy  
 
ELISA 
 
Commercial ELISA kits (RSR Limited) with an automated system (DSX, Technogenetics) were used.  
Reagents were allowed stand at room temperature for at least 30 minutes before use. In each well 25 µl patient 
serum (or an equal amount of CSF), calibrators and controls were deposited. After covering the frame, the wells 
were shaken for 1 hour at room temperature. The samples were then aspirated and the wells washed three times 
with the diluted wash solution. In each well 100 µl of a solution of biotin conjugated with GAD65 were pipetted 
and incubated for one hour at room temperature. The wells were washed three times with the washing solution. 
Afterwards, 100 µl of streptavidin peroxidase solution were pipetted into each well and incubated for 20 minutes 
at room temperature. The wells were washed three times with the washing solution. Then, 100 µl of TMB 
(peroxidase substrate) solution were pipetted into each well and incubated for 20 minutes at room temperature 
without agitation. 100 µl of blocking solution were added and incubated for 5 seconds under agitation. Within 10 
minutes, the absorbance reading was performed in each well at 405 nm. The results of calibrators were plotted in 
a graph representing the logarithmic scale of the concentration versus the absorbance value. Based on this graph 
it was possible to obtain the calibration curve and the samples concentration according to the range of the kit (5 – 
2000 IU/ml).  
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Estimation of titres (modified ELISA) 
For concentration values above 2000 UI/mL an algorithm was applied through serial dilutions at 1:10, 1:320, 
1:640 and 1:1280 for serum; 1:10, 1:80 and 1:160 for CSF. These dilutions were established arbitrarily according 
to preliminary experiments.  
Applying a recently proposed model [87] it was possible to calculate the estimation of the sample concentration 
on the basis of the single results obtained from the serial dilutions. We established that at least one of the results 
was included in the semilinear portion of the sigmoid calibration curve (see below), arbitrarily established in a 
range of ± 0.5 OD compared to the sigmoid flex point; when the point was not inside this range, an intermediate 
or higher dilution was performed.     
The ELISA kit gives the concentration value (range 5 – 2000) starting from an absorbance value, based on the 
relation between concentration and absorbance expressed in the following formula (graphically expressed as a 
sigmoid curve). 
 
 
 
 
where E (Y) is the absorbance revealed by the machine at the concentration of antibody x. The parameters b1, b2, 
b3 e b4 are fixed parameters varying in each experiment; they represent, respectively, the inferior and superior 
asymptote of the curve, the antibody concentration at the level of absorbance (average compared to the two 
asymptotes) and the curve grade (Figure 3). B1, b2, b3 and b4 are calculated by the machine at the beginning of 
each experiment, through a calibration curve starting from samples with known concentration provided by the 
manufacturer. Considering the geometry of the sigmoidal curve, it is possible to observe that close to the 
asymptote, small absorbance variations correspond to very different concentration values. For this reason, the 
precision of the instrument is not constant in determining the antibody concentration, but it is higher at middle 
absorbance levels and lower when the absorbance is near the asymptote levels. Therefore, the arithmetic average 
of multiple dilutions is not precise, rather it is preferable to calculate a ponderate average, based on the position 
of the result in the sigmoidal curve.  
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Figure 3. Sigmoidal curve with parameters b1, b2, b3 and b4 
 
The ponderate average was calculated according to Cheung et al [87] as follows. For sample i, xi  is defined as 
the antibody concentration of the sample, xik is the concentration of the sample diluted K times, dilk is the 
dilution factor, and yik is the absorbance revealed by the machine for the sample diluted K times.  
The natural logarithm of the xik concentration for each k is calculated as follows: 
 
 
 
 
 
 
Then the weighted factor wik is calculated for each k: 
 
 
 
 
Lastly, the natural logarithm of the concentration of undiluted sample is calculated: 
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Therefore the antibody concentration of the sample not diluted can be obtained by the following formula: 
 
 
To speed up the mathematical calculation, an algorithm was created and developed in a computer programme 
(Dr. A. Brieda, dr. S. Bellio).  
 
Intrathecal synthesis calculation 
When paired serum and CSF samples were available, the Link index (IgG index) and antibody index of GADA 
(AIGAD) were calculated, as indicators of IgG intrathecal synthesis and GAD abs intrathecal synthesis, 
respectively. For this purpose, the nephelometric dosage (Siemens) of albumin and IgG were performed on both 
serum and cerebrospinal fluid.  
The Link index was calculated through the following formula:  
 
 
that is 
 
 
 
A value above 0,7 is suggestive of IgG intrathecal synthesis.  
The AIGAD was calculated by the following formula: 
 
AIGAD = QGAD ÷ QIgG 
 
 
 
A value of AI-GAD higher than 1,5 is suggestive of intratechal synthesis of GADA according to the normal 
range for AI. [88] When IgG are predominantly synthesized intrathecally, that is when QIgG > Qlim, the 
following expression is used to better estimate AI   
 
AIGAD = QGAD/QLim 
 
where the limit ratio function (Qlim) is considered:  
[ ])ln(^ xii ex =
QAlbQIgG INDEXIgG ÷=
Serum Alb
CSF Alb
SerumIgG 
CSFIgG 
 INDEXIgG ÷=
SerumIgG 
CSFIgG 
SerumGADA IgG 
CSFGADA IgG 
AIGAD ÷=
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Inter-assay and intra-assay precision 
To evaluate the intra-assay repeatability of ELISA, three dilutions of the same sample were tested four times in 
the same experiment; the dilutions (1:320, 1:640 e 1:1280) were performed by four different operators, using the 
same instruments. The variation coefficients (CV) were evaluated using the following formula:  
 
 
 
 
To evaluate the inter-assay reproducibility of ELISA, the same serum samples were tested in four different 
experiments performed on different days. One serum sample (high GAD abs titre) was diluted at 1:80, 1:320, 
1:640 and 1:1280. The other samples (patients cohort with lower titre) were tested 1:1. The variation coefficient 
(CV) was calculated using the same expression. 
 
Indirect immunohistochemistry 
Serum and CSF were screened by IHC performed on rat cerebellum frozen in 7 µm-thick sections. Rat 
cerebellum was fixed in paraformaldehyde (PFA 2%) for 6 hours. The sections were incubated using patients' 
CSF (1:2) or serum (1:500) for 3 hours at 37°C. After two consecutive PBS washes, the sections were incubated 
with IgG-biotinylated for 30 minutes at room temperature. Reaction was obtained using the avidin-peroxidase 
reagents (ABC Vector reagent) and then developed by DAB staining (Dako). The slides were dehydrated using 
alcohol gradient (70%-96%-96%-100%-100% ethanol and twice washed in xylol). The slides were mounted with 
hydrophobic mount medium (Eukitt). The slides were observed at the optical microscope and the results were 
independently evaluated by two different operators. 
 
Immunoblot 
A commercial kit (Euroimmun) was used to test the serum samples for GAD and onconeural abs. All the 
reagents were kept at room temperature (RT) before using. The washing buffer (10X concentrated) and 
enzymatic conjugate (10x) were correctly diluted. Each strip used for the reaction was located in the respective 
channel and with the number clearly visible. Each channel was filled with 1.5ml of dilution buffer, incubated 5 
minutes in agitation, after which the liquid was discarded. Each channel was then filled with 1.5ml of diluted 
sample (serum 1:100, CSF 1:5) and incubated at RT in agitation. The liquid was discarded and each strip was 
washed 3 times for 5 minutes each with 1.5ml of washing buffer in agitation. 1.5ml of diluted conjugate were 
added in each channel (human IgG conjugated with alkaline phosphatase) and incubated 30 minutes at RT in 
agitation. The strips were then washed as mentioned before. 1.5ml of substrate solution were added and 
QLim(IgG )=0,93×√Qalb2+6×1061,7×103
100
 tirations4  theof average
s titration4  theofdeviation  standard
 CV ×=
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incubated for 10 minutes at RT in agitation. The substrate was then discarded and each strip was washed 3 times 
for one minute with distilled water. The strips were then located in a reference scheme, left to dry at room 
temperature and the results were read by an expert operator.  
 
Cell based assay 
The neuronal surface antibodies were screened using indirect immunofluorescence on commercial (Euroimmun) 
fixed cell lines transfected with vectors expressing the interested antigens (cell-based assay). Briefly, the slides 
contained biochips transfected with cDNA codifying the NMDAR, AMPAR, CASPR1, LGI1 or GABAbR 
antigens. The diluted serum (1:10 with Tween-PBS) and/or non-diluted CSF were incubated for 30 minutes at 
room temperature. The slides were washed for 5 minutes at room temperature in an agitator. The slides were then 
incubated with the secondary antibody (human IgG conjugated with FITC). After a second wash, the slides were 
mounted with glycerol and observed under the fluorescence microscope (Zeiss Aziopoht) at 20X e 40X. The 
results were independently evaluated by two different operators and defined as “positive” or “ negative” when 
the results were in accordance, otherwise the test was repeated.  
 
Statistical analysis 
To evaluate the accuracy of the ELISA test and establish the best cut off, a receiver-operator characteristic (ROC) 
analysis was performed, after determining the true positive cases on the basis of independent clinical analysis 
(typical GAD abs clinical spectrum). The Youden index was applied to find the threshold for higher accuracy 
(confidence intervals 95%).  
Statistical analysis was then applied to the differences between groups using Fisher’s exact test or the Chi-square 
test for categorical variables, Student’s T test and the Mann-Whitney U for quantitative variables, where 
appropriate. Analysis was performed using R statistical software. P-values < 0.05 were considered significant.  
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RESULTS  
Subjects 
Forty-three patients tested positive for serum GAD abs by optimized ELISA (range 6 – 2019681 UI/ml), 35 with 
available clinical information were included in the study. They were 14 males and 21 females, age range 15-82 
years old with the following final reviewed diagnosis: encephalitis (10), SPS (9), ataxia (5), epilepsy (2) and 
other diseases (9). The cases were all reviewed by an independent observer in order to assess the presence of 
typical features resembling GAD autoimmunity as described above. All patients with a diagnosis other than SPS, 
ataxia, epilepsy or epilepsy were excluded to this further clinical analysis and labeled immediately as “Atypical”. 
In 26/35 patients (74%) the final diagnosis belonged to the already reported spectrum of GAD-abs related 
diseases, specifically 10 patients diagnosed with encephalitis, 9 with SPS, 5 with ataxia and 2 with epilepsy. 
Among these, 12/26 failed to fit the criteria described in the methods and were noted as “Atypical”. 14 patients 
showed typical features; they were 9 cases with a final diagnosis of SPS, 3 cases affected by encephalitis and 2 
patients affected by ataxia. No patient diagnosed with epilepsy was noted as “Typical”. Table 2 reports the 
results of this two-step analysis; patients are listed by GAD-abs titre in descending order.  
 
Patient GAD-abs titre Final diagnosis 
GAD- abs 
related 
syndrome? 
Typical features? 
6# 2019681 SPS YES YES 
8# 1373559 Encephalitis YES YES 
9# 1228265 SPS YES YES 
10# 1165654 Epilepsy YES NO 
14# 643289 Ataxia YES YES 
13# 514435 SPS YES YES 
5# 229049 Ataxia YES NO 
7# 226862 SPS YES YES 
4# 187202 Dysartria NO / 
12# 98841 Encephalitis YES YES 
11# 92028 SPS YES YES 
1# 75738 Ataxia YES YES 
3# 53993 SPS YES YES 
15# 51475 Ataxia YES NO 
2# 19440 Encephalitis YES YES 
35# 6547 Corticobasal degeneration NO / 
16# 1182 Encephalitis YES NO 
34# 258 Chronic pain NO / 
21# 224 Morvan syndrome NO / 
19# 219 SPS (PERM) YES YES 
29# 169 SPS YES YES 
27# 49 Encephalitis YES NO 
32# 41 Encephalitis YES NO 
20# 39 SPS (PERM) YES YES 
25# 39 Ataxia YES NO 
17# 29 Encephalitis YES NO 
28# 27 Encephalitis YES NO 
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30# 26 Parkinsonism NO / 
26# 24 Chronic pain NO / 
18# 21 Wernicke NO / 
23# 18 Motor neuropathy NO / 
31# 14 Chronic pain NO / 
22# 11 Encephalitis YES NO 
33# 11 Epilepsy YES NO 
24# 6 Encephalitis YES NO 
 
Table 2. Final diagnosis and assessment of typical features by the external observer 
 
Typical patients were in the great majority women (78%) with a mean age of 50,9 years old (Table 3). 
Oligoclonal bands were one of the supportive data to note the patients as “typical” and were present in 64% of 
typical patients but also in 14% of atypical patients. Patients were treated with immunotherapy in a high 
proportion of cases (27/35); but typical patients more frequently underwent immune-suppression (9/14 versus 
2/21; p < 0,001).    
 
Assessment of the clinically relevant cut-off 
On the basis of the clinical assessment performed as showed above (typical versus atypical cases), a ROC curve 
was built in order to assess the cut-off for the clinical relevance of serum GAD abs detected by our assay (Figure 
4).  
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Figure 4. ROC Curve analysis for GAD abs and the categories “typical” versus “atypical” patients 
 
The area under the curve (AUC) was 0.842 (standard error 0.66; 95 confidence interval 0.713 – 0.971). 
Calculation of the best cut off according to the Youden method [89] was 12993 UI/ml. This cut off identifies two 
groups of patients with either high-titre (> 12993 IU/ml) or low-titre (< 12993 IU/ml) antibodies. 
According to this cut off, the test had a sensitivity = 78.57% (CI 95% 57.08% – 100.07%), specificity = 80.95% 
(64.16% - 97.75%), positive predictive value = 73,33% (50.95% - 95.71%), negative predictive value = 85% 
(69.35% - 100.65), odds ratio = 15.583 (2.90 – 83.46). 
 
Control groups 
53 subjects were tested as controls: 45 were patients affected with neurodegenerative diseases, 14 demyelinating 
diseases and 6 neuropathy; 8 were healthy volunteers. All controls tested negative for GAD abs.      
From October 2016 to October 2017, 215 samples sent for suspected endocrinological diseases (T1DM or 
polyglandular autoimmune syndromes) were tested by ELISA; a total of 43 samples tested positive; 6 (14,0%) 
had a titer between 2000 – 13000 IU/ml; in 2/43 cases (4,7%) GAD abs were higher than the aforementioned 
threshold (65134 and 405093 IU/ml). The neurological status of these subjects is unknown.  
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Figure 5. GAD antibodies levels measured by ELISA in serum of typical patients, atypical patients and of endocrinological controls 
 
Serum GAD abs titer range in typical patients was between 39 – 2019681 IU/ml (mean = 453325) significantly 
higher than atypical patients (range 6 – 1165654, mean = 78186) (p < 0.001) and endocrinological group (range 6 
– 405093, mean = 12069) (p < 0.0001); titers of atypical were not significantly different from endocrinological 
group (p = 0.33) (Figure 5)  
 
Stiff person syndrome 
Patients with a final diagnosis of SPS (Table 3) were 6 females and 3 males (age range 42 – 82, mean 59.3). All 
6 females had serum GAD abs with high titres (53993 – 2019681 IU/ml). The 3 males had titres ranging from 39 
to 219 IU/ml and two of them had a final diagnosis of PERM. These two patients were also tested for Glycine 
receptor (GlyR) antibodies and one of them (patient 19#) was highly positive in the serum (1:800) and CSF. He 
was a 70-year-old man who developed severe encephalopathy with fever, behavioural changes, ocular 
dysfunction, craniofacial spasms, marked myoclonus and startle; he responded brilliantly to rituximab (weekly 
375 mg/m2 for 1 month) after failing with intravenous immunoglobulin. After therapy, the GlyR abs were 
undetectable in the serum but persisted in the CSF; the GAD abs titre also decreased from 219 to 24 IU/ml.   
Five out of 9 patients had comorbidity with other autoimmune diseases. Except in one case, which showed a 
slight protein content increase, standard examination of the CSF was negative; the oligoclonal band pattern was 
found by IEF in 3/6 patients, whereas one patient had a mirror pattern of identical oligoclonal bands in the serum 
and CSF. All patients except patient 19# showed a response to symptomatic therapy with benzodiazepines and at 
least a partial response to immune-treatment was reported in all patients, although only patient #29 had a 
modified rankin scale score of 0 at the last follow up. Notably 5/9 patients underwent immune-suppression with 
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Rituximab (3), Azathioprine (2) and Cyclophosphamide (1).       
       
N. 
Pt 
Sex; 
age at 
onset 
GAD 
serum 
titer 
Clinical features CSF (IEF) EMG Autoimmune 
comorbidity; tumor; 
other neural antibody 
Immunotherapy 
(response?) 
Last MrS (months 
follow up) 
6# F 42 2019681 Subacute onset of left 
leg weakness and 
rigidity; axial and 
limb rigidity with 
spasms; phobias   
Normal 
(OCB) 
MUP firing 
triggered by 
coutaneous 
stimulation. 
Pernicious 
anemia; 
autoimmune 
thyroiditis. 
Steroids, IVIG, 
PEX, Rituximab 
(YES) 
2 (18) 
13# F 51 514435 Insidious onset of 
axial and limb 
stiffness with 
superimposed 
spasms; anxiety 
NA Continuous MUP 
firing. 
Autoimmune 
thyroiditis 
IVIG, PEX, 
Azatyoprine 
(YES) 
1 (150) 
7# F 57 226862 Subacute onset of leg 
rigidity; falls; 
depression and 
anxiety  
NA NA Vitiligo Steroids, IVIG, 
PEX, 
Azatyoprine, 
Rituximab (YES) 
4 (27) 
9# F 65 122865 Slow onset of let leg 
rigidity, than also 
right leg and trunkal 
stiffness; spasms; 
anxiety and 
depression.  
Normal 
(OCB) 
Continuous MUP 
firing; 
co-contraction of 
antagonist muscles 
Pernicious 
anemia; Graves 
disease;  
Steroids, IVIG 
(YES)  
2 (18) 
11# F 52 92028 Axial and limb 
stiffness; spams; 
depression and 
anxiety; spinal 
deformity.  
NA Firing at rest in the 
paraspinal and 
proximal leg 
muscles.   
No. 
Anti-amphiphysin. 
IVIG, PEX 
(YES) 
1 (86) 
3# F 71 53993 Insiodious onset of 
proximal weakness; 
axial and limb 
rigidity with spasms; 
anxiety 
Normal 
(Negative) 
Continous MUP 
firing 
Autoimmune 
thyroiditis. 
Steroids, IVIG 
(YES) 
NA (66) 
19# M 70 219 Subacute onset of 
fever, behavior 
changes, dysarthria, 
dysphagia, 
cranio-facial spasms, 
cranial nerve deficits; 
myoclonus; startles 
and seizures (PERM) 
Normal 
(Negative) 
Spontaneous and 
reflexed 
myoclonus. 
No. Anti-Glycine 
Receptor 
IVIG, Rituximab 
(YES) 
NA (24) 
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29# M 82 169 Subacute onset of 
trunkal and left leg 
rigidity; spasms 
Protein 
content 
increase. 
Mirror 
pattern. 
Continuous MUP 
firing 
No Steroids, IVIG 
(YES) 
0 (16) 
20# M 44 39 Subacute onset of 
axial and lower limb 
stiffness; spasms; gait 
disturbances; anxiety; 
depression. (PERM) 
27 
leukocites; 
OCB + 
Normal No Steroids, IVIG, 
PEX, 
Cyclophosfamide 
(YES) 
1 (54) 
 
Table 3. Clinical data of patients affected by Stiff Person Syndrome (MUP = Motor unit potential, NA = not available information,  
OCB = Oligoclonal Bands; Normal CSF = proteins < 45 mg/dl, leukocites < 5 /mm3) 
 
Encephalitis 
Patients with typical GAD encephalitis (n. 3) (Table 4) were females (age range 27 – 51) all with HT GAD abs 
(19440 – 1373559 IU/ml). They were three females with clinical features of limbic encephalitis and bilateral 
mesio-temporal hyperintensity (Figure 6). Patients 2# was a 51 female that developed limbic encephalitis in the 
context of previously diagnosed stiff person syndrome. Two CSF samples were available, and both were positive 
for oligoclonal bands, whereas cell and protein content was normal. 2/3 had altered electroencephalography and 
2/3 had autoimmune comorbidity. Notably patient 12# was treated with rituximab; outcome of this patient was 
dominated by severe memory deficits reported also in patient 8#.  
7/10 patients with atypical features were 4 males and 3 females 
(age range 15 – 68) and showed GAD Abs ranging from 6 to 1182 
IU/ml. Clinical findings were more aspecific in comparison of 
typical patients; one patient had prominent brainstem involvement 
(patient 16#). Patient 28# had a LGI1 abs positive encephalopathy; 
patient #32 was a typical LGI1 abs positive patient with memory 
deficits and facio-brachial dystonic seizures that had a brilliant 
response to immunotherapy.   
CSF showed signs of inflammation in 4 up to 7 cases; 2/5 
available IEF showed oligoclonal bands. Brain MRI was altered in 
3/7 cases with inflammatory involvement of thalamus (3 cases), 
brainstem and cerebellum. Electroencephalography showed 
pathological findings in 6/7 patients, only in one case suggesting 
involvement of temporal lobes (pt. 28#). 5/7 cases underwent 
immunotherapy and at least partial response was always reported. Only in patient 24# an immune-suppression 
was started with mycophenolate; he was a 64 years old man affected by non-Hodgkin lymphoma; he developed 
 
Figure 6. Brain MRI with hyperintensity of  
mesio-temporal lobes in patient 8#  
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an encephalopathy with signs of inflammation on CSF some months after stem cell transplant. 
  
N. Pt 
Sex; 
age at 
onset 
GAD 
serum 
titer 
Clinical features CSF MRI EEG 
Autoimmune 
comorbidity; 
tumor; other 
neural antibody 
Immunotherapy 
(response?) 
Last MrS 
(months 
follow 
up) 
8# F 32 1373559 
Acute onset of memory deficits, 
confusion and anxiety; 
generalized and temporal 
seizures, dystonia; depression 
OCB + 
Bilateral 
mesio-temporal 
hyperintensity 
Normal 
(inter-ictal 
EEG) 
Autoimmune 
thyroiditis, 
vitiligo, 
psoriasis 
Steroids, IVIG 
(YES) 
2 (8) 
12# F 27 
98841 
 
After flu-like prodrome, acute 
onset of temporal seizures; 
memory deficit, psychosis with 
delusions and hallucinations; 
obsessive-compulsive behaviour. 
OCB + 
Bilateral 
mesio-temporal 
hyperintensity 
Right 
temporal 
spike waves 
Thyroiditis 
Steroids, IVIG, 
Rituximab (YES) 
Severe 
cognitive 
deficit 
( amnesia
) (76) 
2# F 51 19440 
Acute onset with temporal 
seizures; confusion and 
hallucinations; pre-existing limb 
stiffness with superimposed 
spasms  
N.A. 
Bilateral 
mesio-temporal 
hyperintensity 
Diffuse 
spike-and-wa
ve complexes 
No 
Steroids, IVIG, 
PEX (YES) 
NA (28) 
16# M 35 1182 
Subacute diplopia and 
disequilibrium 
OCB + 
Pontomesencephalic 
and bilateral 
thalamic 
hyperintensity 
Normal No 
Steroids, IVIG 
(YES) 
0 (24) 
32# F 68 68 
Acute onset of facio-brachial 
dystonic seizures; cognitive 
impairment.  
Normal 
(OCB -) 
Normal 
Left frontal 
slow waves 
No. Anti-LGI1 
Steroids, IVIG, 
PEX (YES) 
0 (24) 
27# F 36 49 
Insidious onset of memory 
deficit, apathy, vomiting 
headache; generalized seizures. 
Normal. 
OCB - 
Normal 
Slow frontal 
waves 
No 
Steroids, IVIG 
(YES) 
0 (3) 
17# M 46 29 
Acute onset of generalized 
seizures; tetraparesis. 
Increased 
cells 
count; 
OCB NA . 
Right thalamus 
hyperintensity and 
corpus callosum 
Anterior 
spike waves 
No NO 5 (3) 
28# F 67 27 
Slow onset of complex temporal 
seizures, memory loss, depression  
Normal 
(OCB NA) 
Normal 
Bitemporal 
spikes 
Hashimoto 
thyroiditis. 
Anti-LGI1 
Steroids, IVIG, 
PEX (YES) 
NA (13) 
22# M 15 11 
Acute onset of headache, 
confusion, hallucinations, fever, 
vomiting. 
Incresead 
proteit and 
cell (80 
/mm3). 
OCB - 
Thalamic and 
cerebellar focal 
hyperintensity; 
meningeal 
enhancement 
Frontal slow 
waves 
No NO NA (3) 
24# M 64 6 
Subacute onset of confusion and 
apathy; cognitive impairment 
with memory deficit; 
hallucination and delusions; 
delirium 
Increased 
protein and 
cells (80). 
OCB - 
Normal 
Diffuse slow 
waves 
Non Hodgkin 
lymphoma 
Steroids, IVIG, 
mycophenolate 
(YES) 
3 (12) 
 
Table 4. Clinical data of patients affected with encephalitis 
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Ataxia 
Five patients were finally diagnosed with ataxia. (Table 5) Two women (patient #1 and #14, aged 43 and 26 
years respectively) had typical features and both proved to have high serum titers (643289 and 75738 IU/ml). 
Both had positive oligoclonal bands and showed cerebellar atrophy on brain MRI. They underwent treatment 
with partial response and achieved only clinical stabilization.  
In particular, patient #14 started to develop dysarthria and 
disequilibrium at the age of 26 years; two years after, T1DM and 
autoimmune hypothyroidism were diagnosed; she could walk 
successfully unassisted for some kilometers but in 2016 (18 years 
after the onset of the disease) she again started to complain of 
worsening gait and dysarthria. At this time brain MRI revealed 
severe cerebellar atrophy (figure 7); GAD abs were positive at 
high titre in serum and CSF; standard examination of CSF was 
normal, whereas isoelectrofocusing revealed IgG oligoclonal 
bands.     
The patient underwent 5 sessions of PEX without benefit; 
pernicious anemia was also found and treated with parenteral replacing of B12. Immunoglobulin were also not 
effective, whereas azathioprine was not tolerated by the patient and then stopped. Eight months later the patient 
again underwent 5 PEX sessions of plasma-exchange and started weekly maintenance with stabilization of the 
disease. Before and after three consecutive weekly sessions, GAD abs and total IgG were measured. During each 
session the titre decreased by about a half and then grew again up to the next session; a parallel removal kinetics 
of GAD abs and total IgG was observed (Figure 8) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Brain MRI with cerebellar atrophy 
in patient 14# 
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Figure 8. Patient 14# GAD abs and total IgG level before and after three consecutive weekly plasma-exchange sessions (arrows)  
 
Both typical ataxic patients were examined by the author; in a late phase of disease, in adjuction to marked gait 
ataxia (determining disability with mRS = 4), dysarthria and nystagmus, they showed clear signs of overlapping 
SPS features, especially rigidity of abdominal, lumbar paravertebral and leg muscles worsening gait difficulty; 
these symptoms were partially responsive to benzodiazepines and plasma-exchange.  
Three women affected by ataxia were considered atypical; two of them have high titers antibodies (229049 and 
51475 IU/ml), whereas the third had low titer (39 IU/ml) and was the only patient of this group in which 
immunotherapy was not performed.      
 
N. 
Pt 
Sex; 
age at 
onset 
GAD 
serum 
titer 
Clinical features CSF (IEF) MRI Autoimmune 
comorbidity; 
tumor; other 
neural antibody 
Immunotherapy 
(response?) 
Last MrS (months 
follow up) 
14# F 26 643289 Slow onset of 
dyshartria and 
balance impairment; 
abdominal rigidity; 
depression 
Normal 
(OCB) 
Cerebellar atrophy T1DM; 
hypothyroidism; 
autoimmune 
gastritis.  
IVIG, PEX (Yes) 4 (255) 
5# F 80 229049 Subacute onset of 
postural instability; 
vertigo; vomiting; 
nystagmus and 
myoclonus  
Normal 
(negative) 
Normal No Steroids, IVIG 
(Yes) 
3 (12) 
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1# F 43 75738* Vertigo attacks; slow 
onset of gait and limb 
ataxia; dysarthria, 
Diplopia. Axial 
rigidity. 
Normal 
(OCB) 
Cerebellar atrophy Impaired fasting 
glucose 
Steroids, IVIG, 
PEX, Azatyoprine, 
Cyclophosphamide 
(No) 
4 (120) 
15# F 56 51475 Vertigo attacks; 
nystagmus; 
depression 
Normal 
(negative) 
Mild vermian 
atrophy 
T1DM Steroids, IVIG 
(No) 
1 (5) 
25# F 45 39 Slow onset of gait and 
limb ataxia, 
dysarthria; depression  
Normal 
(negative) 
Cerebellar atrophy No No 4 (132) 
 
Table 5. Clinical data of patients affected with cerebellar ataxia (* serum sampled in the chronic phase after immunotherapy) 
 
Epilepsy 
Only two patients had a final diagnosis of epilepsy (Table 6). Patient #10 was a 60-year-old male with slow onset 
of temporal lobe epilepsy which was responsive to antiepileptic drugs; he was also affected with thyroiditis. 
GAD abs were positive at a very high titre whereas standard examination of CSF and IEF were negative. The 
second patient was a 56-year-old male affected by mental retardation who developed status epilepticus which 
responded to treatment. No patient underwent immunotherapy; no patient was considered positive for typical 
features.   
 
N. 
Pt 
Sex; 
age at 
onset 
GAD 
serum 
titer 
Clinical features 
 
CSF (IEF) EEG MRI Autoimmune 
comorbidity; 
tumor; other 
neural antibody 
Immunotherapy 
(response?) 
Last 
MrS 
(months 
follow 
up) 
10# M 60 1165654 Slow onset of 
temporal lobe 
epilepsy; 
responsiveness to 
carbamazepine and 
valproate. 
Mild protein 
increase 
(Negative) 
Left 
fronto-temporal 
epileptiform 
activity 
Normal Chronic 
thyroiditis 
Not performed 0 (97) 
33# M 56 11 Acute onset of 
status epilepticus 
Negative 
(Negative) 
Frontal 
epileptiform 
activity 
Normal No Not performed 2 (4) 
 
Table 6. Clinical data of patients affected with epilepsy 
 
Other diagnosis 
Only one patient (Patient #4) with a final diagnosis other than the classical spectrum of GAD abs (atypical 
patients) tested high-titre positive. She was a 45-year-old woman admitted for speech difficulties which had 
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progressively worsened over three months. T1DM was diagnosed 3 months before the onset of neurological 
manifestations; at the time of DM1 detection, serum GAD abs were negative. Neurological examination showed 
spastic dysarthria associated with jaw jerk and brisk reflexes. Mild weakness was observed of the inferior facial 
muscles. Neither fasciculations nor amyotrophy were documented. Electromyographic recordings from bulbar 
and spinal muscles did not detect any neurogenic/myogenic potentials while limb motor evoked potentials were 
normal; no continuous MUP discharges were recorded. Low frequency repetitive stimulation did not detect 
pathological amplitude decrement. Magnetic resonance imaging studies showed no abnormalities on brain. 
Anti-ACHR and anti-MUSK were negative but GAD abs were detected at high titre in serum (187202 IU/ml) 
and CSF (10933 IU/ml). Diazepam was ineffective for the dysarthria. Eight-monthly 5-day courses of 
intravenous immunoglobulin were administered, followed by azathioprine 3mg/kg/day. A good clinical recovery 
started after the third infusion, with normalization of the GAD abs. After 16 months, dysarthria was mild and 
isolated.  
A further 8 patients with other final diagnoses had low titre antibodies (14–6547 IU/ml). They were diagnosed 
with chronic pain (no. 3), Morvan syndrome with positivity for LGI1 abs (n. 1), corticobasal degeneration (no. 1), 
multifocal neuropathy (no. 1), parkinsonism (no.1), and Wernicke encephalopathy (no. 1). None of these patients 
with available CSF had GAD abs detectable in the CSF or oligoclonal bands; patient #30 had a mirror pattern of 
identical IgG bands in serum and CSF. Only one patient had autoimmune comorbidity (patient #26 affected by 
T1DM). 5/8 patients underwent first-line immunotherapy for a suspected autoimmune disease. 
Patient #35 was a 58-year-old male. He slowly developed behavioural changes, gait imbalance, apathy, 
disinhibition and episodes of delirium. Subsequently he started to develop dysarthria and to be unaware his left 
arm with contemporary dystonic postures of the left hand. Neuropsychological testing revealed severe apraxia. A 
corticobasal syndrome was diagnosed; finding serum GAD abs (6547 IU/ml) led to treatment with 
immunoglobulin with no benefit.    
 
Autoimmune comorbidity 
15/35 (43%) patients were affected by co-existent autoimmune diseases. In typical patients autoimmune 
thyroiditis was highly represented (n. 7) followed by pernicious anemia (n. 3), vitiligo (n. 2), Graves disease (n.1) 
and psoriasis (n.1). In two atypical patients pernicious anemia, autoimmune thyroiditis and Graves disease were 
reported. Four patients (2 typical patients) were affected by T1DM.     
 
CSF GAD abs and intrathecal synthesis 
A total of 26 patients were tested for GAD abs in the CSF; 11 patients tested positive (range 1248 – 55698 
IU/ml). As showed in Table 8, all patients with GAD abs in CSF had high titre GAD abs in the serum. In all 9 
cases with availability of paired serum and CSF, intrathecal GAD-ab synthesis was positive. The GAD antibody 
index (AI) was calculated as reported above.  
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Nine patients had positive oligoclonal bands (OCB) and 2 patients had a identical pattern of OCB in the serum 
and in CSF. Notably, in two cases with negative IgG OCB, intrathecal GAD abs antibody synthesis was showed.     
 
Patient Diagnosis Serum titer CSF titer AI GAD IEF pattern 
6# SPS 2019681 13032 2,2 Oligoclonal 
8# Encephalitis 1373559 55698 14,1 Oligoclonal 
9# SPS 1228265 16432 4,6 ** Oligoclonal 
10# Epilepsy 1165654 9059 1,9 Negative 
14# Ataxia 643288 21601 7,2 Oligoclonal 
1# Ataxia 330016 18388 23,0 Oligoclonal 
5# Ataxia 229049 3645 6,1 Negative 
4# Dysarthria 187202 10933 NA NA 
12# Encephalitis 99152 2963 NA NA 
15# Ataxia 51475 1248 14 Negative 
2# Encephalitis 19440 2708 42,1 ** Oligoclonal 
  
Table 7. Patients with positive GAD abs in CSF; isoelectrofocusing result and Antibody index. (AI-GAD > 1,5 is suggestive of intratechal 
synthesis; ** AI GAD calculated as QGAD/QLim; italic for atypical cases) 
      
 
False positives and false negatives 
The aforementioned cut off led to 4 false positives and 3 false negatives.    
Two false positive patients (ie atypical patients with high-titre GAD abs) were affected with cerebellar ataxia, 
one with dysarthria and another with epilepsy.  
The ataxic patients recorded as being non-typical had negative findings on standard examination of the CSF and 
no oligoclonal bands; patient #5 was the oldest woman in the cohort (80 years of age) and had no autoimmune 
comorbidity; patient #15 did not respond to immunotherapy. Nevertheless, both showed intrathecal synthesis of 
GAD abs in CSF. The epileptic patient was not resistant to therapy and showed no oligoclonal bands on 
immunoelectrofocusing; nevertheless he had temporal epilepsy of long duration and autoimmune comorbidity; 
intrathecal synthesis of GAD abs was found. The patient affected by dysarthria was described above; high-titre 
GAD abs in CSF were found. 
The 3 false negatives (ie typical patients with low-titre GAD abs) were affected by stiff person syndrome 
spectrum (including two patients with PERM phenotype); one of this patient had serum and CSF glycine 
receptor antibodies.  
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Inter-assay and intra-assay precision 
One sample was tested 4 times at three different dilutions in the same session to assess intra-assay precision; one 
sample at four dilutions and other 2 samples were tested in 4 different sessions to assess inter-assay precision. 
The coefficient of variation (CV) was calculated, yielding percentages within usual accepted values (< 10%) 
(Table 8,9 )   
 
 GAD abs IU/ml (n.4) CV (%) 
Sample A 1:320 1365,9 9,8% 
Sample A 1:640 578,6 7,3% 
Sample A 1:1280 235,4 7,7% 
           
Table 8. Intra-assay precision (CV = coefficient of variation) 
 
 GAD abs IU/ml (n.4) CV (%) 
Sample B (1:80) 256,6 4,9% 
Sample B (1:320) 61,3 6,7% 
Sample B (1:640) 32 7,4% 
Sample B 
(1:1280) 
18,2 7,2% 
Sample C 218,8 3,4% 
Sample C 148,9 10,4% 
 
Table 9. Inter-assay precision (CV = coefficient of variation) 
 
Other neural antibodies 
Serum and/or CSF were screened for onconeural antibodies and NsAbs. One patient with a high GAD-abs titre 
showed co-reactivity with anti-Amphyphisin abs; 4/36 (11%) with low-titre GAD abs had a relevant NsAbs 
positivity for anti-LGI1 (3) (two affected with encephalitis and patient 21# affected with Morvan syndrome)  
and anti-GlyR antibodies (1).     
 
Immunoistochemistry and immunoblot 
The serum samples of included patients were also screened for GAD abs by IHC (Figure 9) and commercial 
immunoblot. Positive serum samples showed immunostaining of GABA-ergic nerve terminals on rat cerebellar 
tissue sections (in particular the granular layer and terminal of basket cells on the Purkinje cell layer).   
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Figure 9. Immunohistochemistry on frozen cerebellar tissue (positive sample shows brown diaminobenzidine reactivity with granular and 
Purkinje cell layer; slides counterstained with haematoxilin) 
 
The results of these tests have been reported in the Table 10 and are displayed together with GAD abs titre 
(descending order) and intrathecal synthesis of GAD abs. IHC and IB were positive in patients with typical 
features and high titre antibodies except one SPS patient who tested negative for IB; the lowest value of 
positivity was 226862 IU/ml (both for IHC and IB). Similar results were obtained with immunofluoresce on 
commercial kits (Euroimmun). No patient from endocrinological group tested positive, except the patient with 
the highest titre (405093 IU/ml). 
     
Patient GAD serum Diagnosis GAD IS IHC IB 
6# 2019681 SPS YES POS POS 
8# 1373559 Encephalitis YES POS POS 
9# 1228265 SPS YES POS POS 
10# 1165654 Epilepsy YES POS POS 
14# 643289 Ataxia YES POS / 
13# 514435 SPS Np / NEG 
5# 229049 Ataxia YES / / 
7# 226862 SPS Np POS POS 
4# 187202 Dysartria Np NEG NEG 
12# 98841 Encephalitis Np / / 
11# 92028 SPS Np / NEG 
1# 75738 Ataxia YES NEG NEG 
3# 53993 SPS Np NEG / 
15# 51475 Ataxia YES NEG / 
2# 19440 Encephalitis YES NEG NEG 
35# 6547 CBD NO NEG NEG 
16# 1182 Encephalitis NO / / 
34# 258 Chronic pain NO / / 
21# 224 Morvan syndrome Np NEG NEG 
19# 219 SPS (PERM) NO NEG / 
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29# 169 SPS NO NEG NEG 
27# 49 Encephalitis NO NEG NEG 
32# 41 Encephalitis NO NEG / 
20# 39 SPS (PERM) NO NEG NEG 
25# 39 Ataxia Np NEG / 
17# 29 Encephalitis Np NEG / 
28# 27 Encephalitis NO NEG NEG 
30# 26 Parkinsonism NO NEG NEG 
26# 24 Chronic pain NO NEG / 
18# 21 Wernicke Np NEG / 
23# 18 MMN Np NEG NEG 
31# 14 Chronic pain NO NEG / 
22# 11 Encephalitis NO NEG NEG 
33# 11 Epilepsy NO NEG / 
24# 5,4 Encephalitis NO NEG NEG 
 
Table 10. GAD abs detected by immunoistochemistry (IHC) and immunoblot (IB);  
 “/” means that the test was not available   
 
On the basis of clinical assessment, IHC has specificity =89,47% (CI 66,86 – 98,70), sensitivity = 45,45% (CI 
16,75 – 76,62), positive predictive value = 71,43% (36,68% - 91,52%) and negative predictive value = 73,91 % 
(61,78% - 83,24%).  
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DISCUSSION 
 
Clinical validation of ELISA 
We identified 35 patients with positive serum GAD abs by a modified commercial ELISA. A retrospective 
clinical analysis, based on data already published in literature, established that 14 cases manifested typical 
features of GAD neurological autoimmunity described usually in association with high titers.  
ROC analysis allowed us to identify a cut off (about 13000 IU/ml) of clinical relevance for serum GAD abs 
detected by our technique with good accuracy. All control group subjects tested negative, as differently from a 
previously reported low-titre positivity in 8% of healthy subjects by RIA. [90] The endocrinological control 
group of patients affected by T1DM and polyglandular autoimmune diseases showed titres lower than 13000 
IU/ml in 95% of patients. In our view, these findings are a clinical validation of our method to detect GAD abs in 
serum and CSF of neurological patients. 
    
Today in most large generalist laboratories where diagnostics of neurological autoimmune diseases are 
increasingly being performed, [91] GAD abs are routinely detected by commercial ELISA or RIA validated in 
diabetic patients. These kits identify antibodies at low titres, i.e. the usual range of GAD abs found in T1DM.  
Search for GAD abs in neurological patients have not been standardized so far, differently from diabetes. [52] As 
a consequence, it is difficult to compare values between laboratories due to the heterogeneity of techniques and 
units of measure. This fact has also been cause for confusion in the literature [49] resulting in various cut offs 
being used to distinguish high (relevant in neurological patients) from low titers. (Table 11)  
 
Paper Cut off Disease Technique 
Walikonis, 1998 [90] 20 nmol/L SPS RIA 
Chang, 2013 [19] 1000 U/ml SPS RIA 
Saiz, 2008 [11] 2000 U/ml SPS RIA 
Fouka, 2015 [92] 2000 IU/ml / ELISA 
Alexopoulos, 2013 [37] 20000 IU/ml SPS ELISA 
Vincent 2008 [40] 1000 U/ml / RIA 
 
Table 11. Examples of cut offs used to identify high-titre (relevant) GAD antibodies 
 
Looking at literature, we found a large amount of published papers (data not shown) which disregarded the fact 
that low titers have not a clear role in neurological patients [11], with consequent misleading results and clinical 
messages. Moreover, a common mistake that is encountered also in clinical practice is to consider a titer over the 
threshold of the kit (e.g. 2000 IU/ml) as a final value, without performing further dilutions. This may lead to 
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wrong clinical choices if one considers that the threshold of clinical relevance may be higher and that about 1/5 
patients from our endocrinological cohort had values over that cut off. To give an example of such mistakes, the 
authors of a recent work published by a high impact factor journal failed to show the decrease of GAD abs after 
plasma-exchange because the titre persisted over the 2000 UI/ml; but they did not obtain an effective titration of 
the samples before and after the procedure. [66]        
Our project aimed to answer these uncertainties and to validate a commercially available kit (designed and 
validated for endocrinological purposes), optimizing its use in neurological patients, especially to detect 
antibodies exceeding the kit’s upper threshold (2000 IU/ml) in serum and in CSF. We chose this kit because it is 
widely available and uses international units of measure. We estimated GAD abs titres of diluted samples by 
applying a weighted average estimation approach [87] which uses ponderate values based on the distribution in 
the sigmoid yielded by the experiment. This method provides a better estimation of the titres compared to linear 
methods (this statement, in our context, is based purely on a theoretical assumption and should be confirmed 
empirically). 
International guidelines recommend, as for onconeuronal antibodies for which commercial tests are widely 
available, [93] [94] to screen neurological patients for GAD abs using a two-step method i.e. 
immunohistochemistry (IHC) on rat cerebellum followed by confirmation by another technique, as RIA, ELISA 
[49] or immunoblot. It has been already observed that IHC is very specific in detecting relevant GAD abs in 
neurological patients (we confirmed this observation, as IHC got specificity = 89%); on the other hand, it is 
positive only in very high titre neurological patients (e.g. over 2000 U/ml [11] or 4000 U/ml [19] by different 
commercial RIA kits; note should be taken that the unit of measure does not convert linearly to IU/ml). Notably, 
this criterion is based on one assumption that has not been rigorously validated in a clinical setting to our 
knowledge. Moreover, IHC is often not available in generalist laboratories and interpretation of morphological 
patterns requires high expertise, which is only available in a limited number of reference centres. Our work 
highlights that also patients with intermediate titres (13000 – 200000 IU/ml) could have relevant GAD abs – 
with a clinical profile similar to patients with higher titers - but testing negative to IHC, which achieved a 
sensitivity of 45%. This low sensitivity may be due to differences in the preparation of tissues described in 
similar works [11] [50], although our protocol is comparable to highly sensitive IHC performed for the detection 
of neuronal surface antibodies [95] 
It has been recommended [11] that in the presence of serum positivity for GAD abs, the relevance of these 
findings (to justify, for example, an immunosuppressive treatment) should be based on clinical findings and 
confirmation of intrathecal synthesis, which is very frequent in GAD abs associated diseases. [27] [60] From this 
standpoint, the clinical relevance of our threshold was confirmed by the fact that intrathecal synthesis of GAD 
abs (the observer was blinded to this finding) was only found in patients with high titer (Table 7). Sunwoo in 
2016 [96] reported a series of patients with GAD abs CSF positivity without detection of antibodies in paired 
serum. In that study GAD abs were detected by RIA at very low titres and in a good number of cases patients 
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had a final diagnosis of neurodegenerative disorders. In our experience, since 2009, we have found only one 
positivity on CSF with sero-negativity in a patient affected by multiple sclerosis. Notably in our cohort, 
intrathecal synthesis of GAD abs was found also in two cases with negative IgG oligoclonal bands; this is in line 
with previous observations [39] [60] and with the notion that Antibody Index evaluation is more sensitive than 
oligoclonal band detection by immunoelettrofocusing. [97]      
We confirmed that caution must be taken to handle results from diabetic patients: in two cases we demonstrated 
very high titers in endocrinological group control; this point has been already underlined in one study showing 
that patients affected by T1DM and high-titre GAD abs during a long follow up did not develop neurological 
disturbances. [71]       
 
Clinical features of patients with typical GAD spectrum 
The clinical features of our high-titre patients are similar to the ones already reported in literature. Stiff-person 
syndrome is the most widely-recognized disease associated with GAD abs. [11] With respect to other series of 
GAD abs positive patients, [11] [16] in our work there is an over-representation of patients affected by 
encephalitis (10 cases, 3 typical with a high titre) compared to ataxia (5 cases, 2 typical with high titre). This is 
probably due to a selection bias: our laboratory accepts samples from the whole of Italy for the detection of 
recently described surface neuronal antibodies, particularly in patients affected by encephalitis [98]. In our 
cohort we did not identify patients with clinical manifestation reported more rarely in literature, as myasthenia 
gravis [99] and myelopathy [100]. 
The diagnoses of SPS were all confirmed in our GAD positive patients by clinical retrospective review. SPS has 
specific manifestations and diagnosis is based on clinical and electrophysiological data consistent with spinal 
hyperexcitability [86]. GAD abs are a supportive criterion for the diagnosis, considering that up to 20% of 
patients with a diagnosis within the SPS spectrum can be seronegative. This subgroup of patients more often has 
a limited form of SPS or PERM and can be paraneoplastic in a higher proportion of cases; moreover, they show 
a lower incidence of autoimmune comorbidity. [53] [101] Our 3 patients with low GAD abs had no associated 
autoimmune diseases (compared with all the high-titre patients) and two cases had a PERM phenotype. Notably, 
one patient affected by PERM was positive for Glycine receptor (GlyR) antibodies in serum and CSF. These 
antibodies have recently been described in association with PERM, sometimes in co-existence with GAD abs. 
Moreover, one study recently found GlyR abs in 15% of patients affected by classical SPS. [37] We cannot 
exclude that these low titres of GAD abs may be of relevance, but the different clinical profiles in patients with 
PERM suggest involvement of other antibodies. 
A total of 5 women in our cohort were diagnosed with cerebellar ataxia. Only two patients were considered to 
have typical ataxia on the basis of criteria explained in the methods section. The over-representation of women 
has been confirmed in the most significant series published about this phenotype. [23] [71] Clinical features 
consisting of gait ataxia, diplopia and nystagmus were present; both typical patients in our cohort had a slow 
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onset but subacute onset was also present. We performed repeated cycles of plasma-exchange, obtaining 
stabilization of the disease, in a woman whose conditions had started worsening 18 years after the onset of 
cerebellar ataxia. We showed that the GAD-abs titre decreased after each session, together with total IgG. In the 
following days both the GAD-abs titre and total IgG progressively increased to near pre-treatment values. These 
findings confirm that plasma-exchange is effective in decreasing both the GAD-abs titre and total IgG.. [102] 
[103] The reduction of the GAD abs burden by plasma-exchange has previously been shown in GAD-related 
diseases [104] [105] [106] although, globally, the response to this therapy is partial and transitory. [107] 
A further interesting observation in both our high-titre ataxic patients was the co-existence of rigidity and spasms 
of the lumbar and abdominal muscles and legs in a late phase of the disease. The coexistence of typical 
symptoms of SPS in patients with GAD-abs-related ataxia has already been reported in 26% of patients in a 
single series. [23] These symptoms have already been described after the development of ataxic syndrome [108] 
but in some cases they precede the onset of cerebellar ataxia by a few years, resembling the focal form of SPS. 
[109] 
This finding highlights the notion, which has been clear since the earliest description of stiff person syndrome, 
that there is an overlap of clinical manifestations related to GAD abs. A further such example is a patient from 
our series, who developed a clinical picture of limbic encephalitis (according to the recent clinical diagnostic 
criteria [83]), complicating the picture of a patient affected by SPS. In the series by Malter [47], SLS was 
diagnosed during the course of limbic encephalitis in 2 GAD-abs positive patients. In another case, myoclonus 
[110] and facial cramps were reported during GAD-abs-related encephalitis. [111]  
Clinical features of our patients affected by encephalitis with high titre antibodies, showing clinical, radiological 
and neurophysiological involvement of the mesio-temporal lobes, confirm that this reactivity must be considered 
in the screening of patients affected by limbic encephalitis. [83] The low number of patients with high-titre abs 
did not allow to detect some specific clinical finding that could differentiate this form from encephalitis 
associated to neuronal surface or onconeural antibodies. We confirmed a bad outcome in spite of immunotherapy, 
especially for residual memory deficits, [47] similarly to paraneoplastic limbic encephalitis. [80] Most patients 
affected with encephalitis testing low-titre positive had non-specific features and they did not resemble the 
clinical picture of limbic encephalitis. Nevertheless, a good response to immunotherapy was reported; notably 3 
low-titre patients tested positive for LGI1 abs. One patient had a clinical onset dominated by facio-brachial 
dystonic seizures, that typically associate to LGI1 encephalitis, [112]; she was promptly treated with excellent 
outcome. Another LGI1 positive patient showed more aspecific findings with multifocal encephalopatic 
involvement, whereas the third was a patient diagnosed with Morvan syndrome.        
Epileptic patients harbouring serum GAD abs have been variably considered in the literature. In our view the 
correct approach to take is to consider only high titres of GAD abs as being significant. [76] Nevertheless, there 
are no convincing data describing the clinical features of epileptic patients testing positive for GAD abs. The 
most consistent studies reported temporal epilepsy with frequent drug-resistance and long duration. [77] [113] 
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Due to this uncertainty, our patients were considered atypical, although one patient showed high-titre GAD abs 
(false positive). Observational studies about this specific group of patients could address this issue in the future. 
 
Atypical cases 
In our cohort we identified the unusual case of a 45-year-old Caucasian woman developing spastic dysarthria, 
jaw jerk and brisk reflexes without cerebellar manifestations; mild weakness of the inferior facial muscles was 
observed; these features were associated with the detection of high-titre GAD abs in the serum and CSF and the 
co-existence of T1DM. The patient clearly responded to intravenous immunoglobulin. This case could resemble 
prominent brainstem involvement in some GAD-abs-positive cases already reported by Pittock [100]; in 
particular 4/11 African patients in this series had dysarthria (in some cases described as spastic) in the context of 
more complex brainstem involvement. This case could probably been interpreted as a manifestation of focal 
dysfunction of inhibitory truncal circuits, leading to focal rigidity in absence of the truncal or limb rigidity 
typical of SPS. We also described a 58-year-old male that slowly developed a corticobasal syndrome; finding of 
GAD antibodies on serum (6547 IU/ml) led to treatment with immunoglobulin with no benefit. Oligoclonal 
bands and GAD abs in CSF were negative. In 2014 two patients with high-titre GAD abs positive SPS who have 
signs suggestive of corticobasal syndrome have been described; they had positive oligoclonal bands in CSF. [114] 
These observations highlight that GAD autoimmunity could express with signs resembling clinical phenotypes 
in which an inflammatory pathogenesis could be overlooked.  
 
Autoimmune and paraneoplastic accompaniments  
No tumor accompaniment was detected in our series; this finding confirms that GAD autoimmunity in most 
cases is not associated with a systemic cancer and that careful oncological screening should be limited to GAD 
abs in the context of rare classical paraneoplastic neurological syndrome. [82] [94]  
We confirmed a high association of GAD abs with coexisting autoimmune diseases, especially autoimmune 
thyroid disease and T1DM; [20] this is not a common finding of other antibody-associated neurological 
syndromes (like paraneoplastic disease or autoimmune encephalitis), except for neuromyelitis optica in which  
the most frequent accompaniments are Sjogren syndrome and lupus erythematosus. [115] 
 
Coexistence with other neural antibodies 
Several studies have addressed this issue, in order to establish if autoimmune diseases associated with GAD abs 
could be due to neuronal surface antibodies with higher pathogenic role. [16] [19] [37] [116] 
In our patients with high-titre GAD abs no other known antibody was detected, except one co-reactivity with 
Amphyphisin in one epileptic patient. These onconeural antibodies are usually found in paraneoplastic SPS 
[100]. A very long follow-up for this patient is available (97 months) and no tumor have been detected. 
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Three patients with low-titre GAD abs were found positive for LGI1 abs and one with GlyR antibodies. We did 
not search for anti-gephyrin and GABARAP, which had previously been suggested as possibly having 
co-reactivity with GAD abs. [19]. Whether the coexistence of neuronal surface antibodies with low-titer GAD 
abs is incidental or due to immunologic mechanisms (eg. cross reaction) is difficult to establish (see the next 
section)  
 
Meaning of low-titer GAD abs 
One of our aims was to explore the meaning of low-titre GAD abs, on the basis of our identified threshold. We 
identified 20 patients antibodies under the threshold of 13000 (6 – 6547 IU/ml). Of them, 3/20 (15%) had typical 
GAD abs manifestations (false negatives). 17 patients (true negatives) had atypical features. They were 
prevalently male (10/17; 59%) with a mean age of 49 years. No patient had intrathecal synthesis of GAD abs. 
2/11 (18%) patients had IgG oligoclonal pattern in CSF. 3/17 (18%) had autoimmune comorbidity. 7/20 (35%) 
had a final diagnosis that excluded any autoimmune causes (neurodegenerative or metabolic disorders). However, 
considering that patients showed a partial response to immunotherapy in 9/12 cases (75%) and that in 4 cases 
relevant co-existent antibodies were detected, our data suggest that low titres don not rule out the possibility of 
an underlying autoimmune mechanism, on which grounds, in case of clinical suspicion, a complete neuronal 
autoimmune panel has to be performed. Diagnostic value of low-titre GAD abs is still debated; recently some 
authors have claimed a relevance in some clinical phenotypes, [117] [118] but these data need further 
confirmation because casual association has not been excluded undoubtedly.  
 
Conclusion 
We are aware of the limits of our work, based on retrospective and indirect clinical information, and take due 
caution in proposing a cut off that depends on our data (GAD abs titre is not a normally distributed variable). 
Managing GAD-abs positivity in patients with suspected autoimmune neurological diseases is a very common 
problem in clinical neuroimmunology. Our work provides some suggestions on how to consider the values 
yielded by this specific commercial kit. When addressing GAD positivity in clinical practice, we confirm the 
well-known recommendation to also screen CSF and calculate intrathecal synthesis. We additionally suggest to 
obtain an accurate titration of serum (if possible with standardized units of measure) in order to better consider 
the clinical relevance of GAD abs and to provide the right diagnostic and therapeutic choices for our patients. 
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